GRCE
What one share of Grace Therapeutics holds
Pharmaceutical Preparations
We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes.
Grace Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.20 |
|---|---|
| Cash and investments | $0.85 |
| Book value | $2.96 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$34.80 | — | — | — | $6.79 |
| 2020 | — | −$14.48 | — | −$13.02 | — | $6.74 |
| 2021 | — | −$7.96 | — | −$5.79 | — | $12.82 |
| 2022 | $16.29 | −$1.60 | — | −$2.81 | — | $14.67 |
| 2023 | — | −$5.71 | — | −$2.14 | — | $9.14 |
| 2024 | — | −$1.35 | — | −$1.29 | — | $6.57 |
| 2025 | — | −$0.79 | — | −$1.23 | — | $4.86 |
| 2026 | — | −$0.47 | — | −$0.54 | — | $3.99 |